Effectiveness of the capsaicin 8% patch in the management of peripheral neuropathic pain in European clinical practice: the ASCEND study

Colette Mankowski, Chris D Poole, Etienne Ernault, Roger Thomas, Ellen Berni, Craig J Currie, Cecil Treadwell, José I Calvo, Christina Plastira, Eirini Zafeiropoulou, Isaac Odeyemi, Colette Mankowski, Chris D Poole, Etienne Ernault, Roger Thomas, Ellen Berni, Craig J Currie, Cecil Treadwell, José I Calvo, Christina Plastira, Eirini Zafeiropoulou, Isaac Odeyemi

Abstract

Background: In randomised studies, the capsaicin 8% patch has demonstrated effective pain relief in patients with peripheral neuropathic pain (PNP) arising from different aetiologies.

Methods: ASCEND was an open-label, non-interventional study of patients with non-diabetes-related PNP who received capsaicin 8% patch treatment, according to usual clinical practice, and were followed for ≤52 weeks. Co-primary endpoints were percentage change in the mean numeric pain rating scale (NPRS) 'average daily pain' score from baseline to the average of Weeks 2 and 8 following first treatment; and median time from first to second treatment. The primary analysis was intended to assess analgesic equivalence between post-herpetic neuralgia (PHN) and other PNP aetiologies. Health-related quality of life (HRQoL, using EQ-5D), Patient Global Impression of Change (PGIC) and tolerability were also assessed.

Results: Following first application, patients experienced a 26.6% (95% CI: 23.6, 29.62; n = 412) reduction in mean NPRS score from baseline to Weeks 2 and 8. Equivalence was demonstrated between PHN and the neuropathic back pain, post-operative and post-traumatic neuropathic pain and 'other' PNP aetiology subgroups. The median time from first to second treatment was 191 days (95% CI: 147, 235; n = 181). Forty-four percent of all patients were responders (≥30% reduction in NPRS score from baseline to Weeks 2 and 8) following first treatment, and 86.9% (n = 159/183) remained so at Week 12. A sustained pain response was observed until Week 52, with a 37.0% (95% CI: 31.3, 42.7; n = 176) reduction in mean NPRS score from baseline. Patients with the shortest duration of pain (0-0.72 years) experienced the highest pain response from baseline to Weeks 2 and 8. Mean EQ-5D index score improved by 0.199 utils (responders: 0.292 utils) from baseline to Week 2 and was maintained until Week 52. Most patients reported improvements in PGIC at Week 2 and at all follow-up assessments regardless of number of treatments received. Adverse events were primarily mild or moderate reversible application site reactions.

Conclusion: In European clinical practice, the capsaicin 8% patch provided effective and sustained pain relief, substantially improved HRQoL, improved overall health status and was generally well tolerated in a heterogeneous PNP population.

Trial registration: NCT01737294 Date of registration - October 22, 2012.

Keywords: Capsaicin 8% patch; Health-related quality of life; Neuropathy; Numeric pain rating scale; Pain management; Peripheral neuropathic pain; Topical analgesic.

Figures

Fig. 1
Fig. 1
Schedule of patient assessments. *Numeric pain rating scale (NPRS) ‘average pain during the last seven days’ score was recorded at the screening visit and used as the baseline pain score. NPRS ‘average pain during the last 24 h’ score was recorded at treatment visits and assessments; ‡Week 2 and Week 8 assessments were performed only after first capsaicin 8% patch treatment. EQ-5D, EuroQol 5 Dimension 3-level; PGIC, patient global impression of change
Fig. 2
Fig. 2
Percentage change in mean NPRS ‘average daily pain’ score following first treatment (a) from baseline to Weeks 2 and 8 and (b) from baseline to each assessment. The margin of equivalence for percentage change in mean NPRS score was set at ±16% (comparable to a one-point change on the NPRS scale). Error bars represent 95% confidence intervals. CRNP, cancer-related neuropathic pain; HIV-AN, HIV associated neuropathy; NBP, neuropathic back pain; NPRS, numeric pain rating scale; Other, other non-diabetic PNP; PHN, postherpetic neuralgia; PONP, post-operative and post-traumatic neuropathic pain; W, week
Fig. 3
Fig. 3
Capsaicin 8% patch re-treatment intervals between (a) first and second treatment and second and third treatment; and (b) time between first and second treatment by aetiology group. NBP, neuropathic back pain; Other, other non-diabetic PNP; PHN, postherpetic neuralgia; PONP, post-operative and post-traumatic neuropathic pain

References

    1. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630–5. doi: 10.1212/01.wnl.0000282763.29778.59.
    1. Marchettini P, Lacerenza M, Mauri E, Marangoni C. Painful peripheral neuropathies. Curr Neuropharmacol. 2006;4(3):175–81. doi: 10.2174/157015906778019536.
    1. Torrance N, Smith BH, Bennett MI, Lee AJ. The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain. 2006;7(4):281–9. doi: 10.1016/j.jpain.2005.11.008.
    1. Bouhassira D, Lanteri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of chronic pain with neuropathic characteristics in the general population. Pain. 2008;136(3):380–7. doi: 10.1016/j.pain.2007.08.013.
    1. Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain. 2010;149(2):338–44. doi: 10.1016/j.pain.2010.02.034.
    1. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–73. doi: 10.1016/S1474-4422(14)70251-0.
    1. Haanpää M, Treede RD. Neuropathic Pain. In Lynch ME, Craig KD & Peng PWH (eds). Clinical pain management: a practical guide. Oxford: Wiley-Blackwell; 2010: 281-9.
    1. Wallace JM. Update on pharmacotherapy guidelines for treatment of neuropathic pain. Curr Pain Headache Rep. 2007;11(3):208–14. doi: 10.1007/s11916-007-0192-6.
    1. Gahr M, Freudenmann RW, Hiemke C, Kolle MA, Schonfeldt-Lecuona C. Pregabalin abuse and dependence in Germany: results from a database query. Eur J Clin Pharmacol. 2013;69(6):1335–42. doi: 10.1007/s00228-012-1464-6.
    1. Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490–502. doi: 10.1093/bja/aer260.
    1. Uceyler N, Sommer C. High-dose capsaicin for the treatment of neuropathic pain: what we know and what we need to know. Pain Ther. 2014;3(2):73–84. doi: 10.1007/s40122-014-0027-1.
    1. Backonja M, Wallace MS, Blonsky ER, Cutler BJ, Malan P, Jr, Rauck R, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7(12):1106–12. doi: 10.1016/S1474-4422(08)70228-X.
    1. Clifford DB, Simpson DM, Brown S, Moyle G, Brew BJ, Conway B, et al. A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. J Acquir Immune Defic Syndr. 2012;59(2):126–33. doi: 10.1097/QAI.0b013e31823e31f7.
    1. Irving GA, Backonja MM, Dunteman E, Blonsky ER, Vanhove GF, Lu SP, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12(1):99–109. doi: 10.1111/j.1526-4637.2010.01004.x.
    1. Maihofner C, Heskamp ML. Prospective, non-interventional study on the tolerability and analgesic effectiveness over 12 weeks after a single application of capsaicin 8% cutaneous patch in 1044 patients with peripheral neuropathic pain: first results of the QUEPP study. Curr Med Res Opin. 2013;29(6):673–83. doi: 10.1185/03007995.2013.792246.
    1. Simpson DM, Brown S, Tobias J, the NGX-4010 C107 Study Group. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70(24):2305–13.
    1. Stoker M, Katz N, Van J, Snijder R, Jacobs H, Long S, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomised, double-blind, placebo-controlled study. Diabetologia. 2015;58(Suppl. 1):S32.
    1. Haanpää M, Cruccu G, Nurmikko TJ, McBride WT, Docu Axelarad A, Bosilkov A, et al. Capsaicin 8% patch versus oral pregabalin in patients with peripheral neuropathic pain. Eur J Pain. 2016;20(2):316–28. doi: 10.1002/ejp.731.
    1. Maihofner CG, Heskamp ML. Treatment of peripheral neuropathic pain by topical capsaicin: Impact of pre-existing pain in the QUEPP-study. Eur J Pain. 2014;18(5):671–9. doi: 10.1002/j.1532-2149.2013.00415.x.
    1. European Medicines Agency. Qutenza Product Information. Annex 1: Summary of product characteristics. 2015. Available at: .
    1. Farrar JT, Young JP, Jr, LaMoreaux L, Werth JL, Poole RM. Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain. 2001;94(2):149–58. doi: 10.1016/S0304-3959(01)00349-9.
    1. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33(5):337–43. doi: 10.3109/07853890109002087.
    1. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–108. doi: 10.1097/00005650-199711000-00002.
    1. Hurst H, Bolton J. Assessing the clinical significance of change scores recorded on subjective outcome measures. J Manipulative Physiol Ther. 2004;27(1):26–35. doi: 10.1016/j.jmpt.2003.11.003.
    1. Grant MD, Samson D. Special report: measuring and reporting pain outcomes in randomized controlled trials. Technol Eval Cent Assess Program Exec Summ. 2006;21(11):1–2.
    1. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14(6):1523–32. doi: 10.1007/s11136-004-7713-0.
    1. Anastassiou E, Iatrou CA, Vlaikidis N, Vafiadou M, Stamatiou G, Plesia E, et al. Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. Clin Drug Investig. 2011;31(6):417–26. doi: 10.2165/11589370-000000000-00000.
    1. Markley HG, Dunteman ED, Kareht S, Sweeney M. Real-world experience with once-daily gabapentin for the treatment of postherpetic neuralgia (PHN) Clin J Pain. 2015;31(1):58–65. doi: 10.1097/AJP.0000000000000082.
    1. Simpson DM, Robinson-Papp J, Van J, Stoker M, Jacobs H, Snijder RJ, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42–53. doi: 10.1016/j.jpain.2016.09.008.
    1. Vinik AI, Perrot S, Vinik EJ, Pazdera L, Jacobs H, Stoker M, Long SK, Snijder RJ, van der Stoep M, Ortega E, Katz N. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16:251. doi: 10.1186/s12883-016-0752-7.
    1. Simpson DM, Brown S, Tobias JK, Vanhove GF, the NGX-4010 C107 Study Group. NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study. Clin J Pain. 2014;30(2):134–42.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir